desipramine and Bladder, Overactive
desipramine has been researched along with Bladder, Overactive in 2 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Desipramine was administered again 2 weeks after the last mirabegron dose." | 2.79 | The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. ( Dickinson, J; Krauwinkel, W; Meijer, J; Schaddelee, M; Strabach, G; Tretter, R; van de Wetering, J; van Gelderen, M, 2014) |
"Desipramine is a potential useful treatment for patients with OAB." | 1.40 | Use of desipramine for the treatment of overactive bladder refractory to antimuscarinic therapy. ( Bagadiya, N; Hillelsohn, JH; Kashan, M; Rais-Bahrami, S; Weiss, GH, 2014) |
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Krauwinkel, W | 1 |
Dickinson, J | 1 |
Schaddelee, M | 1 |
Meijer, J | 1 |
Tretter, R | 1 |
van de Wetering, J | 1 |
Strabach, G | 1 |
van Gelderen, M | 1 |
Hillelsohn, JH | 1 |
Rais-Bahrami, S | 1 |
Bagadiya, N | 1 |
Kashan, M | 1 |
Weiss, GH | 1 |
Clinical Trials (2)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
An Open Label, One-sequence, Parallel Study to Compare the Single Dose Pharmacokinetics of YM178 in Healthy Poor or Extensive Metabolisers for CYP2D6 and to Assess the Effect of Multiple Doses of YM178 on the Metabolism of the Model Substrate Metoprolol[NCT01478490] | Phase 1 | 28 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of the CYP2D6 Substrate Desipramine in Healthy Subjects[NCT01478568] | Phase 1 | 28 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
1 trial available for desipramine and Bladder, Overactive
Article | Year |
---|---|
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over S | 2014 |
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over S | 2014 |
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over S | 2014 |
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over S | 2014 |
Other Studies
1 other study available for desipramine and Bladder, Overactive
Article | Year |
---|---|
Use of desipramine for the treatment of overactive bladder refractory to antimuscarinic therapy.
Topics: Adrenergic Uptake Inhibitors; Aged; Aged, 80 and over; Desipramine; Drug Resistance; Female; Humans; | 2014 |